Novel Alphabeta-Binding protein and its peptide derivatives and uses thereof
OwnerBalu Chakravarthyinventor
Life of this patent
Estimating the term…
Abstract
A protein kinase C inhibitor that binds B-amyloid and its peptide derivatives with the same function are disclosed. These may be useful in the treatment of Alzheimer's disease, for example as pseudo vaccines comprising antibodies, or as part of fusion proteins which are able to pass through cell membranes or through the blood-brain barrier. Methods of using the PKC inhibitor and its peptide derivatives for treating Alzheimer's disease are also disclosed.
Claims36
An amino acid sequence selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3 and SEQ ID NO. 4.
An amino acid sequence selected from the group consisting of SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, SEQ ID NO. 9, SEQ ID NO. 10, SEQ ID NO. 11, SEQ ID NO. 12, SEQ ID NO. 13, SEQ ID NO. 14, SEQ ID NO. 15, SEQ ID NO.16, SEQ ID NO. 17, SEQ ID NO. 18 and SEQ ID NO. 19.
A nucleic acid sequence selected from the group consisting of SEQ ID NO. 20, SEQ ID NO. 21, SEQ ID NO. 22, and SEQ ID NO. 23.
(canceled)
A nucleic acid sequence that encodes the polypeptide of claim 32.
The polypeptide of 32 for use in binding β-amyloids.
(canceled)
A fusion protein comprising at least one polypeptide of claim 32 and a cell-permeable peptide.
A fusion protein comprising at least one polypeptide as claimed in claim 32 and a blood-brain barrier permeable agent.
A pseudo-vaccine comprising at least one as claimed in claim 32 and a pharmaceutically acceptable diluent, carrier, vehicle or excipient.
A composition comprising at least one polypeptide as claimed in claim 32 and a pharmacologically acceptable carrier.
The use of the composition of claim 37 as a protein kinase C inhibitor to modulate β-amyloid generation or toxicity.
An amino acid sequence having at least 90% identity to an amino acid sequence selected from the group consisting of SEQ ID NO. 2-SEQ ID NO. 19, wherein the amino acid sequence binds to β-amyloids.
(canceled)
A soluble polypeptide of not more than 174 amino acids comprising at least one of SEQ ID NO. 1 to SEQ ID NO. 19.
A composition comprising SEQ ID NO. 1, SEQ ID NO. 3 or SEQ ID NO. 4 and a pharmacologically acceptable carrier.
Dependencies are inferred from the claim text.